Impact of early disease factors on metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort

Research output: Contribution to journal › Article

Authors

  • Ben Parker
  • Murray B Urowitz
  • Dafna D Gladman
  • Mark Lunt
  • Rachelle Donn
  • Sang-Cheol Bae
  • Jorge Sanchez-Guerrero
  • Juanita Romero-Diaz
  • Daniel J Wallace
  • Ann E Clarke
  • Sasha Bernatsky
  • Ellen M Ginzler
  • David A Isenberg
  • Anisur Rahman
  • Joan T Merrill
  • Graciela S Alarcón
  • Barri J Fessler
  • Paul R Fortin
  • John G Hanly
  • Michelle Petri
  • Kristjan Steinsson
  • Mary Anne Dooley
  • Susan Manzi
  • Munther A Khamashta
  • Rosalind Ramsey-Goldman
  • Asad A Zoma
  • Gunnar K Sturfelt
  • Ola Nived
  • Cynthia Aranow
  • Meggan Mackay
  • Manuel Ramos-Casals
  • Ronald F van Vollenhoven
  • Kenneth C Kalunian
  • Guillermo Ruiz-Irastorza
  • S Sam Lim
  • Diane L Kamen
  • Christine A Peschken
  • Murat Inanc
  • Ian N Bruce

Colleges, School and Institutes

External organisations

  • University of Manchester

Abstract

The metabolic syndrome (MetS) may contribute to the increased cardiovascular risk in systemic lupus erythematosus (SLE). We examined the association between MetS and disease activity, disease phenotype and corticosteroid exposure over time in patients with SLE.

Details

Original languageEnglish
JournalAnnals of the Rheumatic Diseases
Publication statusPublished - 1 Apr 2014
Save citation Saved citations (0)

Copy the text from this field...

View graph of relations

DOI

By the same authors

Belimumab after B cell depletion therapy in patients with systemic lupus erythematosus (BEAT Lupus) protocol: a prospective multicentre, double-blind, randomised, placebo-controlled, 52-week phase II clinical trial

Caroline Gordon, 16 Dec 2019, In : BMJ open. 9, 12, p. 1-9 9 p., e032569.

Research output: Contribution to journal › Article

Population- based prevalence and incidence estimates of primary discoid lupus erythematosus from the Manhattan Lupus Surveillance Program

Caroline Gordon, 30 Oct 2019, In : Lupus Science and Medicine. 6, 1, p. e000344 7 p., e000344.

Research output: Contribution to journal › Article

Soluble urokinase plasminogen activator receptor (suPAR) levels predict damage accrual in patients with recent-onset systemic lupus erythematosus

Caroline Gordon, 17 Oct 2019, In : Journal of Autoimmunity. 106, 8 p., 102340.

Research output: Contribution to journal › Article

Economic evaluation of damage accrual in an international SLE inception cohort using a multi-state model approach

Caroline Gordon, 14 Oct 2019, In : Arthritis Care & Research.

Research output: Contribution to journal › Article

Prescription opioid use in patients with and without systemic lupus erythematosus — Michigan Lupus Epidemiology and Surveillance program, 2014–2015

Caroline Gordon, 27 Sep 2019, In : Morbidity and Mortality Weekly Report. 68, 38, p. 819–824 6 p.

Research output: Contribution to journal › Article